Viewing Study NCT01087151


Ignite Creation Date: 2025-12-24 @ 11:45 PM
Ignite Modification Date: 2026-02-22 @ 8:40 PM
Study NCT ID: NCT01087151
Status: COMPLETED
Last Update Posted: 2016-11-02
First Post: 2010-03-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Sponsor: Genentech, Inc.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Rituxan View
None Apoptosis View
None BCl-2 View